A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Jassal, B.
- An Overview of Development of Diagnostic Plan for Premenstrual Syndrome
Authors
1 Punjab Institute of Medical Sciences Jalandhar, Punjab, IN
Source
International Journal of Medical and Dental Sciences, Vol 2, No 1 (2013), Pagination: 65-69Abstract
Premenstrual syndrome is a psychoneuroendocrine disorder of unknown etiology. It is characterized by a large number of symptom constellations with various characteristic pattern of appearance&disappearance. The Luteal phase symptom pattern of sufficient severity is the mainstay for diagnosing this condition&needs to be confirmed by prospective charting. Variety of tools with different rating scales & criteria are available for this purpose. The article reviews these tools & criteria to reach a consensus statement for diagnosis of Premenstrual syndrome.Keywords
Premenstrual Syndrome, Luteal Phase Pattern, Criteria, Tools.Full Text
- Cardiodepressant Activity of 90% Alcoholic Extract of Terminalia Arjuna and its Probable Mechanism of Action
Authors
1 Punjab Institute of Medical Sciences Jalandhar, Punjab, IN
2 Government Medical College, Patiala, Punjab, IN
3 Maharishi Markandeshwar Medical College & Hospital Haryana, IN
Source
International Journal of Medical and Dental Sciences, Vol 2, No 2 (2013), Pagination: 144-152Abstract
Background:Terminalia arjuna is being used in various cardiovascular diseases as cardiotonic, diuretic&in hypercholesterolemia. Studies conflict each other for its mechanism of action. This study aims to investigate effect of 90% alcoholic extract of Terminalia arjuna on in vitro isolated rabbit's heart&to find its probable mechanism of action.Objective: To study the preliminary pharmacological effects of 90% alcoholic extract of Terminalia arjuna in-vitro on isolated heart, coronary blood flow, and to study its probable mechanism of action.
Material&Methods: Effect of Terminalia arjuna was observed on heart rate, coronary blood flow, amplitude on in vitro isolated perfused rabbit's heart mounted on langendorff apparatus&further cholinergic&adrenergic blockers were used to study the mechanism of action. Six experiments were conducted for each parameter&data was analysed using Student's t test.
Results: Terminalia arjuna causes mean percentage decrease of 7.26%, 9.31%&20.51% in heart rate, decrease of 10.34%, 16.64%, 20.51% in coronary blood flow&decrease of 15.11%, 12.61%, 11.65% in amplitude at 25μg, 50μg&100μg doses respectively. The decrease in heart rate, coronary blood flow&litude persists even after cholinergic&adrenergic blockers suggesting that cholinergic&adrenergic receptors are not involved in mechanism of Terminalia arjuna.
Conclusion: Terminalia arjuna cardiodepressant effect does not involve cholinergic&adrenergic receptors.
Keywords
Terminalia Arjuna, Alcoholic Extract, Aqueous Extract, Cardiac Depressants.Full Text
- New Ray of Hope for Psychosis in Parkinsons:Pimavanserin
Authors
1 Department of Pharmacology, Punjab Institute of Medical Sciences, Jalandhar, Punjab, IN
Source
International Journal of Medical and Dental Sciences, Vol 5, No 2 (2016), Pagination: 1347-1349Abstract
Parkinson's disease is often associated with hallucinations and psychosis. Till now typical and atypical antipsychotics (Clozapine&Quetiapine) are being used to manage these symptoms. Recently US FDA has approved a new drug Pimavanserin for the treatment of hallucination and delusion associated with parkinson's disease psychosis in a dose of 34 mg.Keywords
Hallucinations, Delusions, Psychosis, Parkinsonism, Pimavanserin.Full Text
References
- Olanow CW, Schapira AHV, Obeso JA. Parkinsons disease and other movement disorders. In: Kasper, Fauci, Hauser, Longo Jameson, Loscalzo, editors. Harrisons principles of internal medicine 19th ed. New York: Mc Graw Hill Education; 2015.p.2617.
- Highlights of prescribing information. Available at: www.access data.fda.gov/drugsatfda_docs/label/2016/207318lbl.pdf. Accessed on 15.05.2016.
- Cummings J, Isaacson S, Mills R, Williams H, Chi-burris K, Corbett A, et al. Pimavanserin for patients with parkinson’s disease psychosis: a randomised, placebo- controlled phase 3 trial. The Lancet. http://dx.doi.org/10.1016/S0140-6736(13)62157-1.